Cargando…
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
BACKGROUND: Safety and effectiveness of aflibercept with 5‐fluorouracil/levofolinate/irinotecan have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a real-world clinical setting. METHODS: This post-marketing surveillance enrolled patients with un-resectable advanc...
Autores principales: | Watanabe, Jun, Terazawa, Tetsuji, Yamane, Shiho, Kazama, Hirotaka, Uetake, Hiroyuki, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823052/ https://www.ncbi.nlm.nih.gov/pubmed/36307632 http://dx.doi.org/10.1007/s10147-022-02259-w |
Ejemplares similares
-
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
por: Hamaguchi, Tetsuya, et al.
Publicado: (2019) -
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2012) -
Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
por: Denda, Tadamichi, et al.
Publicado: (2019) -
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018) -
Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)